You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

Filter Results

Search all journals

Enter search terms…

Advanced search

/

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

Copyright © 2026 by Sage Publications.京ICP备09090397号-11

Search results

Search results page

Articles (147)

Journals (0)

1-10 of 147 results for programmed death ligand 1/2

Sort by:

Relevance

Select all

Select all

Sort by:

Relevance

Select article: Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity

Retricted access

Research article

First published 2020-6

Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity

Shinya Hirahara, Yasuhiro Katsumata, Hidenaga Kawasumi [...]

Lupus

Select article: Clinicopathological significance and prognostic implication of programmed death-1 ligand 2 expression in colorectal cancer

Open access

Research article

First published 2019-9

Clinicopathological significance and prognostic implication of programmed death-1 ligand 2 expression in colorectal cancer

Jung-Soo Pyo, Byoung Kwan Son, Kwang Hyun Chung [...]

The International Journal of Biological Markers

Select article: Lymphocyte cytosolic protein 2 is a novel prognostic marker in lung adenocarcinoma

Open access

Research article

First published 2021-11

Lymphocyte cytosolic protein 2 is a novel prognostic marker in lung adenocarcinoma

Yishan Huo, Kainan Zhang, Songtao Han [...]

Journal of International Medical Research

Select article: Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab

Free access

Review article

First published 2017-5

Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab

Nathan D. Gay, Craig Y. Okada, Andy I. Chen [...]

Therapeutic Advances in Hematology

Select article: Clinical Experience of External Application of Clearing Heat and Removing Dampness in Relieving Grade 2 to 3 Rash Caused by Programed Cell Death Protein 1 (PD-1)/Programed Cell Death Ligand 1 (PD-L1) Inhibitors: A Single-Center Retrospective Study

Open access

Research article

First published 2024

Clinical Experience of External Application of Clearing Heat and Removing Dampness in Relieving Grade 2 to 3 Rash Caused by Programed Cell Death Protein 1 (PD-1)/Programed Cell Death Ligand 1 (PD-L1) Inhibitors: A Single-Center Retrospective Study

Shu-yi Chen, Fang-min Zhao, Rui Yu [...]

Integrative Cancer Therapies

Select article: Emerging role of checkpoint blockade therapy in lymphoma

Free access

Review article

First published 2017-2

Emerging role of checkpoint blockade therapy in lymphoma

Natalie Galanina, Justin Kline, Michael R. Bishop

Therapeutic Advances in Hematology

Select article: Optimizing Sequence of PD-L1 Immune-Checkpoint Inhibitors and Radiation Therapy in Bladder Cancer

Open access

Research article

First published 2020

Optimizing Sequence of PD-L1 Immune-Checkpoint Inhibitors and Radiation Therapy in Bladder Cancer

Côme Tholomier, Gautier Marcq, Surashri Shinde-Jadhav [...]

Bladder Cancer

Select article: TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy

Open access

Research article

First published 2024

TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy

Aditya Bardia, Lajos Pusztai, Kathy Albain [...]

Therapeutic Advances in Medical Oncology

Select article: TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer

Open access

Research article

First published 2025

TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer

Peter Schmid, Mafalda Oliveira, Joyce O’Shaughnessy [...]

Therapeutic Advances in Medical Oncology

Select article: Nivolumab in renal cell carcinoma: latest evidence and clinical potential

Free access

Review article

First published 2017-3

Nivolumab in renal cell carcinoma: latest evidence and clinical potential

Camille Mazza, Bernard Escudier, Laurence Albiges

Therapeutic Advances in Medical Oncology

1
2
3
•••
15
10 / page

Article type

Publication date

Subjects

Access